Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection
暂无分享,去创建一个
J. Hoxie | S. Minoguchi | Yuetsu Tanaka | H. Tamamura | Y. Koyanagi | S. Peiper | M. Waki | T. Murakami | N. Fujii | N. Yamamoto | A. Matsumoto | Tianyuan Zhang | H. Shida | Jin Kim | Y. Suzuki | Tian-yuan Zhang | Yoishihiro Suzuki
[1] M. Baba,et al. T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.
[2] O. Yoshie,et al. T-Tropic Human Immunodeficiency Virus Type 1 (HIV-1)-Derived V3 Loop Peptides Directly Bind to CXCR-4 and Inhibit T-Tropic HIV-1 Infection , 1998, Journal of Virology.
[3] R. Doms,et al. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. , 1998, Journal of reproductive immunology.
[4] R. Doms,et al. An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 1998, Journal of Virology.
[5] R. Doms,et al. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] E. De Clercq,et al. Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.
[7] Miriam K. Konkel,et al. The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[8] A. Otaka,et al. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.
[9] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[10] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[11] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[12] Zi-Xuan Wang,et al. CXCR4 Sequences Involved in Coreceptor Determination of Human Immunodeficiency Virus Type-1 Tropism , 1998, The Journal of Biological Chemistry.
[13] M. Kannagi,et al. Human T-cell leukemia virus type 1 Tax protein induces the expression of lymphocyte chemoattractant SDF-1/PBSF. , 1998, Virology.
[14] S. Durell,et al. Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.
[15] S. Nisole,et al. Spontaneous Mutations in the env Gene of the Human Immunodeficiency Virus Type 1 NDK Isolate Are Associated with a CD4-Independent Entry Phenotype , 1998, Journal of Virology.
[16] R. Doms,et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.
[17] J. Kira,et al. Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo , 1997, Journal of virology.
[18] R. Doms,et al. A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.
[19] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[20] N. Yoshida,et al. A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.
[21] R. Doms,et al. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.
[22] Y. Kirino,et al. Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog. , 1997, Biochemistry.
[23] A. Trkola,et al. Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.
[24] D. Littman,et al. Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.
[25] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[26] N. Heveker,et al. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.
[27] R. Doms,et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[28] K. Peden,et al. STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.
[29] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[30] R. Doms,et al. CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4 , 1996, Cell.
[31] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[32] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[33] A. Garzino-Demo,et al. The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.
[34] M. Baggiolini,et al. HIV blocked by chemokine antagonist , 1996, Nature.
[35] Bernhard Moser,et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.
[36] J. Sodroski,et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.
[37] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[38] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[39] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[40] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[41] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[42] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[43] E. Bradbury,et al. Structure and Polymorphism of HIV-1 Third Variable Loops (*) , 1996, The Journal of Biological Chemistry.
[44] E. De Clercq,et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.
[45] K. Boulez,et al. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. , 1996, European journal of biochemistry.
[46] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[47] K. Boulez,et al. The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV‐1 shows pronounced helical character in solution , 1995, FEBS letters.
[48] E. Bradbury,et al. Local and Global Structural Properties of the HIV-MN V3 Loop (*) , 1995, The Journal of Biological Chemistry.
[49] A. Otaka,et al. Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection. , 1995, Chemical & pharmaceutical bulletin.
[50] A. Otaka,et al. Structure-activity relationships of an anti-HIV peptide, T22. , 1994, Biochemical and biophysical research communications.
[51] Y. Koyanagi,et al. Cell type-specific heterogeneity of the HIV-1 V3 loop in infected individuals: selection of virus in macrophages and plasma. , 1994, Virology.
[52] H. Kikutani,et al. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] T. Honjo,et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. , 1993, Science.
[54] H. Tamamura,et al. Antimicrobial activity and conformation of tachyplesin I and its analogs. , 1993, Chemical & pharmaceutical bulletin.
[55] D. Kohda,et al. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. , 1993, Biochimica et biophysica acta.
[56] T Ueda,et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). , 1992, Biochemical and biophysical research communications.
[57] N. Fujii,et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion , 1992, Antimicrobial Agents and Chemotherapy.
[58] E. Hunter,et al. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. , 1992, Virology.
[59] S. M. Stearns,et al. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity , 1992, Journal of virology.
[60] C. Cheng‐Mayer,et al. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.
[61] B. Chesebro,et al. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages , 1991, Journal of virology.
[62] D. Dimitrov,et al. Initial stages of HIV-1 envelope glycoprotein-mediated cell fusion monitored by a new assay based on redistribution of fluorescent dyes. , 1991, AIDS research and human retroviruses.
[63] N. Fujii,et al. Interactions of an antimicrobial peptide, tachyplesin I, with lipid membranes. , 1991, Biochimica et biophysica acta.
[64] C. Cheng‐Mayer,et al. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene , 1991, Nature.
[65] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[66] H. Vinters,et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.
[67] H. Gendelman,et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.
[68] H. Yoshiyama,et al. Narrow host range of AIDS-related retroviruses (YU-1, 2, 3, 4) isolated from Japanese hemophiliacs: inability to infect H9, Molt-4, and MT-4 cells. , 1986, Japanese journal of cancer research : Gann.
[69] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[70] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[71] A. Otaka,et al. Unambiguous synthesis of stromal cell-derived factor-1 by regioselective disulfide bond formation using a DMSO–aqueous HCl system , 1998 .